Blastic Plasmacytoid Dendritic Cell Neoplasm clinical trials at UCLA
2 in progress, 1 open to eligible people
Engineered Donor Grafts (Orca-T) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
open to eligible people ages 18-75
This study will evaluate the safety, tolerability, and efficacy of an engineered donor graft ("Orca-T", a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.
Los Angeles, California and other locations
IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
Sorry, in progress, not accepting new patients
This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease.
Los Angeles, California and other locations
Our lead scientists for Blastic Plasmacytoid Dendritic Cell Neoplasm research studies include Gary Schiller Caspian Oliai.
Last updated: